A report published by Tel Aviv University on Thursday stated that Israeli researchers have developed a treatment that can prevent developmental and autism. According to Xinhua Net report, research has been done with mice model. And they found that early therapy with the peptide NAP (nucleosomotion protein) normalizes the development of ADNP (activity-dependent neuroprotective protein) syndrome in children. One of the main causes of developmental delay and autism in children is the genetic mutation.
The ADNP gene plays a role in the development of cognition. In most cases, embryos with partial ADNP deficiency will suffer from mental retardation and autism.
In recent years, autistic children with mental retardation have random mutations in the ADNP gene, with the development of genetic sequencing technology that appears to occur during pregnancy.
The resulting protein is shorter than usual, thus suffering from incomplete ADNP (which is ADNP syndrome).
According to the report, researchers found that mice with ADNP produced only about half of the synapses (the link points between nerve cells) compared to healthy mice – especially in the brain areas responsible for the cognitive activity.
These mice showed developmental delay, social difficulty and sensitivity, such as children with mental retardation and autism.
In the next step, followed by nasal spray to mice who waived breastfeeding, the NAP peptide was injected daily into the affected mice from the birthplace.
The results were, however, very impressive: the treated mice were developed normally. They could distinguish between known and unknown mice, had proper memory and developed strength in their muscles. In fact, the brains of these mice began to produce a proper number of synapses.
Published: November 16, 2018, 14:42